Skip to content

Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • Lyme Disease
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-4800
      • TNX-801
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us
October 2023

 Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in a Preclinical Model

October 2023

Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade–Based Immunosuppression

October 2023

WVC Europe: A Novel Mpox Vaccine (Horsepox Platform) to Enhance Preparedness and Global Vaccine Equity

October 2023

FPWR: A planned phase 2, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of TNX-2900 for the treatment of patients with Prader-Willi syndrome

September 2023

CICON: mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated CT26.WT Subcutaneous and CT26-Luciferase Orthotopic Syngeneic Colorectal Cancer Models by Targeting MDSCs in BALB/C Mice

September 2023

IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons, the Expression of which is Dramatically Increased by Inflammation

September 2023

IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons: Expression Increased by Inflammation

June 2023

ATC: aCD154mAb (TNX-1500) Alone, or in Combination with Rapamycin, MMF, or aCD28mAb (VEL-101) Prolongs Cynomolgus Cardiac Allograft Survival

June 2023

ATC: Fc-Modified Anti-CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications

June 2023

ATC: Efficacy of CD154 Blockade with TNX-1500 to Prevent Heart Allograft Immune Injury

Posts navigation

Older posts
Newer posts
Sign up for Email Alerts
  • Compliance
  • Privacy Policy
  • Terms of Service
  • Site Map

© 2026 Tonix Pharmaceuticals Holding Corp.